ArticleNeuro-oncology advances

Blood group O attributes to prolonged progression-free survival, overall survival, and 5-year survival in isocitrate dehydrogenase-wildtype glioblastoma patients with MGMT promoter methylation.

Rainer Wiewrodt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.